These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36905644)

  • 21. Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials.
    Pezzulla D; Macchia G; Cilla S; Buwenge M; Ferro M; Bonome P; Romano C; Zamagni A; Valentini V; Morganti AG; Deodato F
    Clin Exp Metastasis; 2021 Dec; 38(6):519-526. PubMed ID: 34651242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer.
    Zhao X; Zhu X; Fei J; Ren H; Cao Y; Ju X; Yuan Z; Zhang H
    Radiat Oncol; 2018 Oct; 13(1):205. PubMed ID: 30348187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study.
    Mazzola R; Fersino S; Ferrera G; Targher G; Figlia V; Triggiani L; Pasinetti N; Lo Casto A; Ruggieri R; Magrini SM; Alongi F
    Med Oncol; 2018 Aug; 35(9):121. PubMed ID: 30076479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic Body Radiotherapy for Lung Metastases from Colorectal Cancer: Prognostic Factors for Disease Control and Survival.
    Qiu H; Katz AW; Chowdhry AK; Usuki KY; Singh DP; Metcalfe S; Cheruvu P; Chen Y; Okunieff P; Milano MT
    Am J Clin Oncol; 2018 Jan; 41(1):53-58. PubMed ID: 26270442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic body radiation therapy (SBRT) for patients with oligometastatic/oligoprogressive adrenal metastases: Outcomes and toxicities profile in a monoinstitutional study.
    Facondo G; Vullo G; Valeriani M; Ascolese AM; De Sanctis V; Osti MF
    Cancer Treat Res Commun; 2021; 29():100481. PubMed ID: 34700142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereotactic body radiotherapy for pulmonary oligometastases: a monoinstitutional analysis of clinical outcomes and potential prognostic factors.
    Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Nicosia L; Ricchetti F; Rigo M; Attinà G; Vitale C; Pastorello E; Ruggieri R; Alongi F
    Strahlenther Onkol; 2022 Oct; 198(10):934-939. PubMed ID: 35499694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases.
    Voglhuber T; Kessel KA; Oechsner M; Vogel MME; Gschwend JE; Combs SE
    BMC Cancer; 2020 Jun; 20(1):536. PubMed ID: 32513136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
    von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
    Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
    Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salvage Stereotactic Body Radiotherapy (SBRT) Following In-Field Failure of Initial SBRT for Spinal Metastases.
    Thibault I; Campbell M; Tseng CL; Atenafu EG; Letourneau D; Yu E; Cho BC; Lee YK; Fehlings MG; Sahgal A
    Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):353-60. PubMed ID: 26383680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
    Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases.
    Fumagalli I; Bibault JE; Dewas S; Kramar A; Mirabel X; Prevost B; Lacornerie T; Jerraya H; Lartigau E
    Radiat Oncol; 2012 Sep; 7():164. PubMed ID: 23014094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients.
    Scorsetti M; Alongi F; Filippi AR; Pentimalli S; Navarria P; Clerici E; Castiglioni S; Tozzi A; Reggiori G; Mancosu P; Ricardi U
    Acta Oncol; 2012 May; 51(5):618-23. PubMed ID: 22263925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
    Cheung P; Patel S; North SA; Sahgal A; Chu W; Soliman H; Ahmad B; Winquist E; Niazi T; Patenaude F; Lim G; Heng DYC; Dubey A; Czaykowski P; Wong RKS; Swaminath A; Morgan SC; Mangat R; Keshavarzi S; Bjarnason GA
    Eur Urol; 2021 Dec; 80(6):693-700. PubMed ID: 34399998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereotactic Robotic Body Radiotherapy for Patients With Unresectable Hepatic Oligorecurrence.
    Berkovic P; Gulyban A; Nguyen PV; Dechambre D; Martinive P; Jansen N; Lakosi F; Janvary L; Coucke PA
    Clin Colorectal Cancer; 2017 Dec; 16(4):349-357.e1. PubMed ID: 28462852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer.
    Franzese C; Badalamenti M; Teriaca A; De Virgilio A; Mercante G; Cavina R; Ferrari D; Santoro A; Spriano G; Scorsetti M
    J Cancer Res Clin Oncol; 2021 May; 147(5):1307-1313. PubMed ID: 33471186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SBRT for oligoprogressive oncogene addicted NSCLC.
    Basler L; Kroeze SG; Guckenberger M
    Lung Cancer; 2017 Apr; 106():50-57. PubMed ID: 28285694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?
    Merino Lara T; Helou J; Poon I; Sahgal A; Chung HT; Chu W; Soliman H; Ung Y; Verma S; Cheema P; Cheng S; Khanna S; Erler D; Zhang L; Cheung P
    Lung Cancer; 2018 Oct; 124():219-226. PubMed ID: 30268464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
    Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
    Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.